One To Watch

Biocodex

A family-owned pharmaceutical group best known for its long-standing work in microbiota care, alongside established women’s health brands and a focused rare-disease (notably pediatric epilepsy) franchise.

Company Overview

Biocodex develops and markets healthcare products across three main business areas: microbiota care, women’s health, and orphan diseases. The group’s heritage is closely tied to Saccharomyces boulardii CNCM I-745, a probiotic yeast strain that underpins a major portion of its microbiota portfolio.

Headquarters and Global Presence

Biocodex is headquartered in Gentilly, France. The company operates through a network of international subsidiaries and long-term distribution partners across more than 100 countries.

Founding and History

Founded in 1953, Biocodex initially built its business around probiotic yeast for human medicine and later expanded into women’s health and rare diseases. In orphan diseases, its best-known product is stiripentol (Diacomit) for Dravet syndrome, which helped establish the company’s position in rare pediatric epilepsies.

Therapy Areas and Focus

Biocodex’s activities sit across:

Microbiota care: products intended to support gut microbiota balance, including use alongside antibiotic courses in certain markets.
Women’s health: intimate health and related self-care categories, with brands positioned for use across life stages.
Orphan diseases: rare epilepsies as the historical core, with recent steps to broaden into additional rare neurological and lysosomal disorders via partnering.

Technology Platforms and Modalities

Biocodex is not positioned as a single-platform R&D biotech. Its capabilities are best described as:

Microbiota-focused product development anchored in a defined probiotic yeast strain and related research programs.
Consumer-health and OTC-style product development and lifecycle management in women’s health.
Specialty pharma development and commercialization for orphan indications, including formulation work and label expansion efforts.

Key Personnel

Nicolas Coudurier, Chief Executive Officer
Jean-Marie Lefèvre, Chairman of the Board of Directors

Strategic Partnerships

Biocodex uses partnerships to expand both geography and portfolio:

September 4, 2025: equity investment in MRM Health as part of a wider collaboration framework around microbiome-based therapeutics.
July 29, 2025 (agreement dated July 1, 2025): exclusive licensing deal with taiba Middle East for Diacomit (stiripentol) in Gulf Cooperation Council markets.
February 11, 2026: licensing agreement with THX Pharma (Theranexus) covering Batten-1 and TX01 in defined territories, adding late-stage and clinical-stage rare-disease candidates to the portfolio.

FAQ Section

Biocodex is built around product development and commercialization in microbiota care, women’s health, and orphan diseases. Its microbiota business is historically linked to Saccharomyces boulardii CNCM I-745, while its orphan-disease presence is anchored by stiripentol (Diacomit) in Dravet syndrome.

The group prioritizes microbiota-related health solutions, women’s intimate health, and rare diseases—particularly pediatric and neurologic indications—where it can combine specialty-market expertise with partner-enabled expansion.

The established foundation is Diacomit (stiripentol) for Dravet syndrome, supported by ongoing lifecycle work and regional expansion through licensing partners. More recently, Biocodex has moved to broaden its rare-disease scope via in-licensing, including programs in Batten disease, Niemann-Pick disease type C, and Gaucher disease (type 1).

Most recent items, in reverse chronological order:

February 11, 2026: Biocodex and THX Pharma announced a licensing agreement for Batten-1 (Batten disease) and TX01 (Niemann-Pick disease type C and Gaucher disease type 1 in specified territories). Batten-1 was described as preparing for Phase III, with initiation planned for 2026.
November 4, 2025: Biocodex set a decarbonization target to reduce CO₂ emissions by 30% across scopes 1–3 by 2032 and reported recognition under the “Engagé RSE” label.
September 4, 2025: Biocodex announced an equity investment in MRM Health, with a broader collaboration framework discussed as taking the overall partnership value to approximately €30 million.
July 29, 2025 (agreement dated July 1, 2025): Biocodex announced an exclusive licensing agreement with taiba Middle East for Diacomit in GCC markets.

The arrangement is structured around division of labor: THX Pharma leads clinical development for Batten-1 with Biocodex support, while Biocodex takes responsibility for regulatory filings, market access, and commercialization in the licensed territories. For TX01, the program is positioned as an adapted oral formulation of an already approved active ingredient, with the stated aim of improving administration in lysosomal storage diseases.

It indicates Biocodex is supplementing its established microbiota product base with exposure to next-generation microbiome therapeutics via minority investment and collaboration structures. The practical implication is optionality: access to innovation without shifting the core business away from marketed products.

Key watchpoints are execution and late-stage progress:

Start and progress of the planned Phase III program for Batten-1 in 2026 and clarity on regulatory strategy and endpoints.
Any disclosed clinical timelines and territory strategy for TX01 in Niemann-Pick disease type C and Gaucher disease type 1.
Further portfolio moves in microbiota care (including partnerships and publications) and measurable rollout of the company’s stated sustainability program (notably supply chain and manufacturing-related emissions drivers).

Want to Update your Company's Profile?